88 completed, 38 terminated, 16 recruiting, 15 active not recruiting. 90 Phase 2, 79 Phase 1, 13 Phase 3, 4 Not applicable.
Follow Seagen Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer Enfortumab vedotin, Pembrolizumab - Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | Matthew Galsky | 75 | 2025-04-07 | 2026-08-05 |
| Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer Biopsy, Biospecimen Collection, Enfortumab Vedotin - Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 21 | 2024-06-24 | 2026-07-16 |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2024-04-17 | 2026-04-23 |
| Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer Tucatinib in Combination of Oral VP16 and trastuzumab - HER2-positive Breast Cancer | Phase 2 | Recruiting | Institut Curie | 66 | 2023-12-19 | 2025-03-27 |
| Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection - Leptomeningeal Metastasis, Leptomeningeal Disease | Phase 2 | Recruiting | UNICANCER | 30 | 2023-12-18 | 2025-11-18 |
| Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study Tucatinib, Trastuzumab, Pertuzumab - Breast Cancer | Phase 1 | Recruiting | The Netherlands Cancer Institute | 30 | 2023-12-18 | 2024-01-11 |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab - Hodgkin Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2023-12-14 | 2026-10-06 |
| A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection Enfortumab Vedotin - Urothelial Cancer | Recruiting | Astellas Pharma Korea, Inc. | 228 | 2023-11-01 | 2026-10-20 | |
| Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology Biospecimen Collection, Computed Tomography, Enfortumab Vedotin - Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma | Phase 2 | Recruiting | Emory University | 25 | 2023-09-26 | 2026-07-29 |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Tucatinib, Doxil - Breast Cancer | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 36 | 2023-07-24 | 2026-03-20 |
| Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer | Phase 2 | Suspended | Gruppo Oncologico del Nord-Ovest | 477 | 2023-05-17 | 2026-02-03 |
| A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) Trastuzumab emtansine, Tucatinib - Metastatic Solid Tumor, Brain Metastases | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2023-05-16 | 2026-07-16 |
| A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain Tucatinib - Metastatic Breast Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 9 | 2023-05-09 | 2026-02-13 |
| Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Mogamulizumab, Brentuximab vedotin - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Suspended | University of Alabama at Birmingham | 10 | 2023-05-01 | 2026-06-15 |
| Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer Tucatinib, Trastuzumab, Vinorelbine - HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma | Phase 2 | Terminated | Spanish Breast Cancer Research Group | 13 | 2023-03-08 | 2025-12-10 |
| A Safety Study of Brentuximab Vedotin in Participants With HIV brentuximab vedotin, Placebo, ART - Human Immunodeficiency Virus | Phase 1 | Withdrawn | Seagen Inc. | 2022-12-31 | 2023-02-14 | |
| Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. Alpelisib, Tucatinib, Fulvestrant - HER2-positive Metastatic Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Criterium, Inc. | 40 | 2022-08-25 | 2026-03-16 |
| Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer Enfortumab vedotin, Pembrolizumab - Urothelial Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 27 | 2022-06-02 | 2026-10-13 |
| TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases Tucatinib, Pembrolizumab, Trastuzumab - Breast Cancer, Brain Metastases | Phase 1 / Phase 2 | Withdrawn | Reva Basho | 2022-06-01 | 2022-07-01 | |
| Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer Margetuximab, Tucatinib, Capecitabine - Metastatic Breast Cancer, Advanced Breast Cancer | Phase 2 | Withdrawn | MedSIR | 2022-05-15 | 2022-07-11 |
Showing 20 of 171. Sign in to see all of them.
Hodgkin Disease (32) · Hematologic Diseases (31) · Lymphoma (26) · Lymphoma, Non-Hodgkin (22) · Breast Neoplasms (19) · Lymphoma, Large B-Cell, Diffuse (15) · Carcinoma, Non-Small-Cell Lung (14) · Lymphoma, Large-Cell, Anaplastic (12) · Urinary Bladder Neoplasms (12) · Leukemia, Myeloid, Acute (10) · Neoplasms (10) · Ovarian Neoplasms (9) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoma, B-Cell (8)
Brentuximab Vedotin (67) · tucatinib (28) · pembrolizumab (18) · Doxorubicin (17) · enfortumab vedotin (17) · Trastuzumab (15) · Dacarbazine (13) · Rituximab (10) · Vinblastine (9) · dacetuzumab (9) · Gemcitabine (8) · Carboplatin (7) · Cyclophosphamide (7) · Nivolumab (7) · Prednisone (7)
United States (151) · Canada (30) · Spain (30) · France (29) · Italy (28) · United Kingdom (26) · Belgium (17) · Germany (17) · Australia (15) · Poland (14) · Czechia (13) · South Korea (12) · Denmark (11) · Hungary (10) · Japan (10)
Corinna Palanca-Wessels, MD, PhD (4) · JoAl Mayor, PharmD, BCOP (4) · Nancy Whiting, PharmD (4) · Andrew Sandler, MD (3) · Dana Kennedy, PharmD (3) · Jonathan Drachman, MD (3) · Joseph Woolery, PharmD, BCOP (3) · Phoenix Ho, MD (3) · Thomas Manley, MD (3) · Zejing Wang, MD, PhD (3) · Elaina Gartner, MD (2) · Eric Feldman, MD (2)
PMID 39368039, PMID 41044356, PMID 22510871, PMID 37496366, PMID 40135712, PMID 24239220, PMID 25135998, PMID 29804905, PMID 36041086, PMID 12097283, PMID 12752100, PMID 18079362, PMID 19466965, PMID 19557623, PMID 19636010, PMID 19789316, PMID 20038235, PMID 20133895, PMID 21047225, PMID 22080439, PMID 22454421, PMID 22614995, PMID 22775314, PMID 22786877, PMID 22801961, PMID 23624209, PMID 23719719, PMID 23754575, PMID 24359243, PMID 24642247, PMID 24652992, PMID 24919462, PMID 25142258, PMID 25533035, PMID 25573987, PMID 25651427, PMID 25683846, PMID 25796459, PMID 26195720, PMID 26377597, PMID 26994848, PMID 27432875, PMID 27436849, PMID 27458003, PMID 27831508, PMID 27868471, PMID 27986716, PMID 28473406, PMID 28600132, PMID 28903943
2015 (3), 2017 (3), 2023 (3), 2008 (2), 2019 (2), P30CA015704 (2), 2009 (1), 2016 (1), 2018 (1), P01CA018029 (1), P30CA015083 (1), P30CA060553 (1), P30CA093373 (1), P30CA138292 (1), U10CA180821 (1)